Redx Pharma

RXC004 2mg dose selected for Phase II trials

Lighthouse | 27 July 2021

Share this note

  • Results from RXC004’s Phase I dose-escalation study show promising safety and tolerability, and a 2mg once daily (oral) dose will be used in the planned Phase II studies. The first of these proof-of-concept trials, with RXC004 evaluated as monotherapy, is expected to start during H221. Additional studies, in combination with immuno-oncology treatments (such as checkpoint inhibitors), will follow.
  • RXC004 is a novel porcupine inhibitor that targets the Wnt pathways, a series of signalling systems implicated in the initiation and progression of many difficult to treat solid cancers. Inhibiting porcupine selectively impacts tumour growth driven by specific gene mutations, such as RNF43 and fusions in the RSPO gene family. These are often found in colorectal, biliary, and pancreatic cancers, with preclinical studies suggesting tumours carrying the relevant mutations appear particularly sensitive to porcupine inhibition.
  • Results from the Phase I study are expected to be presented at the ESMO congress in September. The trial enrolled patients with a variety of advanced solid tumours but, being a safety study, these were not selected for the relevant genetic mutations. The Phase II studies will address patients with the appropriate sensitivities in genetically selected MSS mCRC and pancreatic cancer, and include all patients in biliary cancer (where typically c 70% have high Wnt expression). Preliminary data, expected in H222, will give the first true indications of clinical efficacy.
  • RXC004 is also being evaluated in Phase I safety studies in combination with a checkpoint inhibitor, with completion expected before end-2021. Efficacy will also be evaluated in similar proof of concept Phase II trials in combination with immuno-oncology therapy, where the opportunity to overcome Wnt driven tumour immune evasion would be highly attractive.

Trinity Delta view: Redx Pharma has an enviable record of developing differentiated “best in class” compounds. This is due primarily to its undoubted medicinal chemistry expertise. Management has created an attractive, and well balanced, clinical portfolio; with two in-house assets (RXC004 and RXC007) and two partnered programmes (AstraZeneca and Jazz Pharmaceuticals). The progression of RXC004 into Phase II trials marks an important milestone in the development of this lead programme and follows the recent de-risking of the regulatory pathway for ROCK2 inhibitor RXC007. Our rNPV model, employing deliberately conservative assumptions, generates a £350.7m valuation, equivalent to 128p/share (86p fully diluted).


27 July 2021

Market Cap£155.3m
Primary exchangeAIM London
Company CodeREDX
Corporate clientYes

Company description

Redx Pharma specialises in the discovery and early clinical development of small molecule therapeutics, with an emphasis on oncology and fibrotic disease. Typically, these are progressed through proof-of-concept studies and then partnered for further development. The strategy has been validated by several collaborations.


Lala Gregorek
+44 (0) 20 3637 5043

Franc Gregori
+44 (0) 20 3637 5041


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2021 Trinity Delta Research Limited. All rights reserved.